Fragment library design considerations

Wiley Interdisciplinary Reviews: Computational Molecular Science

Volumn 2, Issue 6, 2012, Pages 868-885

  Boyd, Susan M ^a   Turnbull, Andrew P ^b   Walse, Björn ^c  

^a ST JOHN S COLLEGE   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c SARomics Biostructures AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867360796     PISSN: 17590876     EISSN: 17590884     Source Type: Journal    
DOI: 10.1002/wcms.1098     Document Type: Article

References (117)

1. Fink T, Bruggesser H, Reymond JL. Virtual exploration of the small-molecule chemical universe below 160 daltons. Angew Chem Int Ed 2005, 44:1504-1508.
2. Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 1996, 16:3-50.
3. Chessari G, Woodhead A. From fragment to clinical candidate-a historical perspective. Drug Disc Today 2009, 14:668-675.
4. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Disc Today 2004, 9:430-431.
5. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase sctivity. J Med Chem 2009, 52:379-388.
6. Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, Zhou L, Keyvan M, Enache L, Sullins D, Onua E, et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]-butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem 2010, 53:573-585.
7. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Deborah J, Davis DJ, Devine LA, Early TR, Feltell RE, et al. Identification of N-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008, 51:4986-4999.
8. Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, Cosme D, Graham JB, Day PJ, Downham R, et al. Discovery of (2, 4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010, 53:5956-5969.
9. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
10. Hubbard RE, Murray JB. Experiences in fragment-based lead discovery. Meth Enzymol 2011, 493:509-531.
11. Siegal G, Ab E, Schultz J. Integration of fragment screening and library design. Drug Discov Today 2007, 12:1032-1039.
12. Murray CW, Carr MG, Callaghan O, Chessari G, Congreve M, Cowan S, Coyle JE, Downham R, Figueroa E, Frederickson M., et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 2010, 53:5942-5955.
13. Köster H, Craan T, Brass S, Herhaus C, Zentgraf M, Neumann L, Heine A, Klebe G. A small non-rule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. J Med Chem 2011, 54:7784-7796.
14. Shoichet B. Screening in a spirit haunted world. Drug Disc Today 2006, 11:607-615.
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 2001, 46:3-26.
16. Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery?. Drug Disc Today 2003, 8:876-877.
17. L. J Med Chem 2006, 49:656-663.
18. Leach AR, Hann MM. Molecular complexity and fragment-based drug discovery: ten years on. Curr Opin Chem Biol 2011 15:489-496.
19. Hajduk PJ. Fragment-based drug design: how big is too big? J Med Chem 2006, 49:6972-6976.
20. Carr RAE, Congreve M, Murray CW, Rees DC. Fragment-based lead discovery: leads by design. Drug Disc Today 2005, 10:987-992.
21. Walters WP, Green J, Weiss JR, Murcko MA. What do medicinal chemists actually make? A 50-year retrospective. J Med Chem 2011, 54:6405-6416.
22. Baurin N, Aboul-Ela F, Barril X, Davis B, Drysdale M, Dymock B, Finch H, Fromont C, Richardson C, Simmonite H, et al. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 2004, 44:2157-2166.
23. Chen I-J, Hubbard RE. Lessons for fragment library design: analysis of output from multiple screening campaigns. J Comput Aid Mol Des 2009, 23:603-620.
24. Schuffenhauer A, Ruedisser S, Marzinzik A, Jahnke W, Selzer P, Jacoby E. Library design for fragment based screening. Curr Topics Med Chem 2005, 5:751-762.
25. Hadjuk PJ, Galloway WRJD, Spring DR. Drug discovery: a question of library design. Nature 2011, 470:42-43.
26. Hung AW, Ramek A, Wang Y, Kaya T, Wilson JA, Paul A, Clemons PA, Young DW. Route to three-dimensional fragments using diversity-oriented synthesis. Proc Natl Acad Sci U S A, 2010, 108: 6799-6804.
27. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005, 45:177-182.
28. Molecular operating environment, version 2010.10. Chemical Computing Group, Inc.: Montreal, Canada.
29. Shibata S, Zhang Z, Korotkov KV, Delarosa J, Napuli A, Kelley AM, Mueller N, Ross J, Zucker FH, Buckner FS, et al. Screening a fragment cocktail library using ultrafiltration. Anal Bioanal Chem 2011, 401:1585-1591.
30. Affinity capillary electrophoresis method for assessing a biological interaction of a ligand/receptor pair such as G protein coupled receptor and its targets as well as for drug screening. Patent pending, PCT/GB2010/051574.
31. Duong-Thi M-D, Meiby E, Bergström M, Fex T, Isaksson R, Ohlson S. Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal Biochem 2011, 414:138-146.
32. Wartchow CA, Podlaski F, Li S, Rowan K, Zhang X, Mark D, Huang K-S. Biosensor-based small molecule fragment screening with biolayer interferometry. J Comput Aid Mol Des 2011, 25:669-676.
33. Shuker SB, Hajduk PJ, Meadows RP, Fresik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
34. Hajduk PJ. SAR by NMR: putting the pieces together. Mol Interv 2006, 6:266-272.
35. Klages J, Coles M, Kessler H. NMR-based screening: a powerful tool in fragment-based drug discovery. Mol Biosyst 2006, 2:319-331.
36. Mayer M, Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 1999, 38:1784-1788.
37. Dalvit C, Pevarello P, Tatò M, Veronesi M, Vulpetti A, Sundström M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 2000, 18:65-68.
38. Siriwardena AH, Tian F, Noble S, Prestegard JH. A straightforward NMR-spectroscopy-based method for rapid library screening. Angew Chem Int Ed Engl 2002, 41:3454-3457.
39. Vanwetswinkel S, Heetebrij RJ, van Duynhoven J, Hollander JG, Filippov DV, Hajduk PJ, Siegal G. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem Biol 2005, 12:207-216.
40. Zheng CJ, Han L, Yap CW, Xie B, Chen YZ. Progress and problems in the exploration of therapeutic targets. Drug Disc Today 2006, 11:412-420.
41. Früh V, Zhou Y, Chen D, Loch C, Ab E, Grinkova YN, Verheij H, Sligar SG, Bushweller JH, Siegal G. Application of fragment-based drug discovery to membrane proteins: identification of ligands of the integral membrane enzyme DsbB. Chem Biol 2010, 17:881-891.
42. Swann SL, Song D, Sun C, Hajduk PJ, Petros AM. Labeled ligand displacement: extending NMR-based screening of protein targets. ACS Med Chem Lett 2010, 1:295-299.
43. Rupp B. Biomolecular Crystallography: Principles, Practice, and Application to Structural Biology. 1st ed. New York: Garland Sci; 2009. ISBN: 978-0-8153-4081-2.
44. Scapin G. Structural biology and drug discovery. Curr Pharm Des 2006, 12:2087-2097.
45. Manjasetty BA, Turnbull AP, Panjikar S, Büssow K, Chance MR. Automated technologies and novel techniques to accelerate protein crystallography for structural genomics. Proteomics 2008, 8:612-625.
46. Verlinde CLMJ, Rudenko G, Hol WGJ. In search of new lead compounds for trypanosomiasis drug design: a protein structure-based linked-fragments approach. J Comput Aid Mol Des 1992, 6:131-147.
47. Verlinde CLMJ, Kim H, Bernstein BE, Mande SC, Hol WGJ. Anti-Trypanosomiasis Drug Development Based on Structures of Glycolytic Enzymes. In: Veerapandian, ed. Structure-based drug design. New York: Marcel Dekker; 1997, 365-394.
48. Gibbs AC, Abad MC, Zhang, X, Tounge BA, Lewandowski FA, Struble GT, Sun W, Sui Z, Kuo LC. Electron density guided fragment-based lead discovery of ketohexokinase inhibitors. J Med Chem 2010, 53:7979-7991.
49. Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. Fragment-based screening using surface plasmon resonance technology. J Biomol Screen 2009, 14:337-349.
50. Edfeldt FNB, Folmer RHA, Breeze AL. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Disc Today 2011, 16:284-287.
51. Griffey RH, Swayze EE, Ligand SAR. Using Electrospray Ionization Mass Spectrometry. In: Jahnke W, Erlanson DA, eds. Fragment-Based Approaches in Drug Discovery. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. doi: 10.1002/3527608761.ch13.
52. Hannah VV, Atmanene C, Zeyer D, Van Dorsselaer A, Sanglier-Cianférani S, Native MS: an 'ESI' way to support structure- and fragment-based drug discovery. Future Med Chem 2010, 2:35-50.
53. Pantoliano MW, Salemme FR, Carver TE. High throughput method for functionally classifying proteins identified using a genomics approach. US Patent Publication: US 7122321.
54. Cummings MD, Farnum MA, Nelen MI. Universal screening methods and applications of ThermoFluor®. J Biomol Screen 2006, 11:854-863.
55. Lo MC, Aulabaugh A, Jin G, Cowling R, Bard J, Malamas M, Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal Biochem 2004, 332:153-159.
56. Matulis D, Kranz JK, Salemme FR, Todd M. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using Thermofluor. Biochemistry 2005, 44:5258-5266.
57. Kranz JK, Schalk-Hihi C. Protein thermal shifts to identify low molecular weight fragments. Meth Enzymol 2011, 493:277-298.
58. Boettcher A, Ruedisser S, Erbel P, Vinzenz D, Schiering N, Hassiepen U, Rigollier P, Mayr LM, Woelcke J. Fragment-based screening by biochemical assays: systematic feasibility studies with trypsin and MMP12. J Biomol Screen 2010, 15:1029-1041.
59. Matthews TP, Klair S, Burns S, Boxall K, Cherry M, Fisher M, Westwood IM, Walton MI, McHardy T, Cheung K-MJ, et al. Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 2009, 52:4810-4819.
60. Barker JJ, Barker O, Boggio R, Chauhan V, Cheng RKY, Corden V, Courtney SM, Edwards N, Falque VM, Fusar F., et al. Fragment-based identification of HSP90 inhibitors. Chem Med Chem 2009, 4:963-966.
61. Black E, Breed J, Breeze AL, Embrey K, Garcia R, Gero TW, Godfrey L, Kenny PW, Morley AD, Minshull CA., et al. Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett 2005, 15:2503-2507.
62. Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comp Sci 1998, 38:511-522.
63. Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay Murcko MA, Moore JM. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol 1999, 6:755-769.
64. Kolb P, Caflisch A. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. J Med Chem 2006, 49:7384-7392.
65. Vieth M, Siegel MG, Higgs RE, Watson IE, Robertson DH, Savin KA, Durst GL, Hipskind PA. Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 2004, 47:224-232.
66. Baurin N, Baker R, Richardson C, Chen I, Foloppe N, Potter A, Jordan A, Roughley S, Parratt M, Greaney P, et al. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds. J Chem Inf Comput Sci 2004, 44:643-651.
67. Ji H, Stanton BZ, Igarashi J, Li H, Martásek P, Roman LJ, Poulos TL, Silverman RB. Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. J Am Chem Soc 2008, 130:3900-3914.
68. Bohm H-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aid Mol Des 1992, 6:61-78.
69. Eisen MB, Karplus M, Hubbard RE. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994, V19:199-221.
70. Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, Murray CW. Docking performance of fragments and druglike compounds. J Med Chem 2011, 54:5422-5431.
71. GOLD. Cambridge Crystallographic Data Centre: Cambridge, United Kingdom.
72. Mazanetz MP, Ichihara O, Law RJ, Whittaker M. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method. J Cheminformatics 2011, 3:2
73. Kitaura K, Ikeo E, Asada T, Nakano T, Uebayasi M. Fragment molecular orbital method: an approximate computational method for large molecules. Chem Phys Lett 1999, 313:701-706.
74. Watanabe H, Tanaka S. Fragment molecular orbital method: application to protein-ligand binding. Interdisciplinary Bio Central 2010, 2:1-5. doi: 10.0451/ibc.2010.2.2.0006.
75. Huggins DJ, Venkitaraman AR, Spring DR. Rational methods for the selection of diverse screening compounds. ACS Chem Biol 2011, 6:208-217.
76. Xu J. A new approach to finding natural chemical structure classe. J Med Chem 2002, 45:5311-5320.
77. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996, 261:470-489.
78. Degen J, Rarey M. Flexnovo: structure-based searching in large fragment spaces. ChemMedChem 2006, 1:854-868.
79. Dean PM, Firth-Clark S, Harris W, Kirton SB, Todorov NP. SkelGen: a general tool for structure-based de novo ligand design. Expert Opinion Drug Discov 2006, 1:179-189.
80. Wang R, Gao Y, Lai L. LigBuilder: A multi-purpose program for structure-based drug design. J Mol Model 2000, 6:498-516.
81. Pearce BC, Langley DR, Kang J, Huang H, Kulkarni A. E-Novo: an automated workflow for efficient structure-based lead optimization. J Chem Inf Model 2009, 49:1797-1809.
82. Lippert T, Schulz-Gasch T, Roche O, Guba W, Rarey M. De novo design by pharmacophore-based searches in fragment spaces. J Comp Aid Mol Des 2011, 25:931-945. doi: 10.1007/s10822-011-9473-6.
83. Seco J, Luque FJ, Barril X. Binding site detection and druggability index from first principles. J Med Chem 2009, 52:2363-2371.
84. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem 1996, 39:2887-2893.
85. Brewer M, Ichihara O, Kirchhoff C, Schade M, Whittaker M. Assembling a Fragment Library. In: Zartler ER, Shapiro M, eds. Fragment-Based Drug Discovery: A Practical Approach. Chichester: John Wiley & Sons; 2008, 46-65.
86. Lepre CA. Library design for NMR-based screening. Drug Disc Today 2001, 6:133-140.
87. Moore J, Abdul-Manan N, Fejzo J, Jacobs M, Lepre C, Peng J, Xie X. Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design. J Synchrotron Rad 2004, 11:97-100.
88. Blomberg N, Cosgrove DA, Kenny PW, Kolmodin K. Design of compound libraries for fragment screening. J Comp Aid Mol Des 2009, 23:513-525.
89. Lau WF, Withka JM, Hepworth D, Magee TV, Du YJ, Bakken GA, Miller MD, Hendsch ZS, Thanabal V, Kolodziej SA, et al. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. J Comput Aid Mol Des 2011, 25:621-636.
90. Schulz MN, Landström J, Bright K, Hubbard RE. Design of a fragment library that maximally represents available chemical space. J Comput Aid Mol Des 2011, 25:611-620.
91. Tounge BA, Parker MH. Designing a diverse high-quality library for crystallography-based FBDD screening. Methods Enzymol 2011, 493:321-356.
92. Spurlino JC. Fragment screening purely with crystallography. Methods Enzymol 2011, 493:3-20.
93. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, Mishra R, Pease B, Erik Hansen E, Singh J, Zembower D, et al. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem 2009, 52:4694-4715.
94. (unpublished results). General kinase fragment library design. Details can be obtained from IOTA Pharmaceuticals Ltd., St John's Innovation Centre, Cambridge, CB4 0WS, United Kingdom.
95. Agrawal A, Johnson SL, Jacobsen JA, Miller MT, Chen L, Pellecchia M, Cohen SM. Chelator fragment libraries for targeting metalloproteinases. Chem Med Chem 2010, 5:195-199.
96. Fritzson I, Svensson B, Al-Karadaghi S, Walse B, Wellmar U, Nilsson UJ, Thrige DDG, Jönsson S. Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection. ChemMedChem 2010, 5:608-617.
97. Walse B, Dufe VT, Svensson B, Fritzson I, Dahlberg L, Khairoullina A, Wellmar U, Al-Karadaghi S. The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry 2008, 47:8929-8936.
98. Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 2009, 5:358-364.
99. Navratilova I, Hopkins AL. Fragment screening by surface plasmon resonance. ACS Med Chem Lett 2010, 1:44-48.
100. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004, 3:301-317.
101. Wilson CG, Arkin MR. Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. Curr Top Microbiol Immunol 2011, 348:25-59.
102. Petros AM, Dinges J, Augeri DJ, Baumeister SA, Betebenner DA, Bures MG, Elmore SW, Hajduk PJ, Joseph MK, Landis SK, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006, 49:656-663.
103. Saraboji K, Håkansson M, Genheden S, Diehl C, Qvist J, Weininger U, Nilsson UJ, Leffler H, Ryde U, Akke M, et al. The carbohydrate-binding site in galectin-3 is preorganized to recognize a sugar-like framework of oxygens: ultra-high resolution structures and water dynamics. Biochemistry 2012, 51:296-306. doi: 10.1021/bi201459p.
104. Albert JS, Blomberg N, Breeze AL, Brown AJ, Burrows JN, Edwards PD, Folmer RH, Geschwindner S, Griffen EJ, Kenny PW, et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 2007, 7:1600-1629.
105. Crisman TJ, Bender A, Milik M, Jenkins JL, Scheiber J, Sukuru SCK, Fejzo J, Hommel U, Davies JW, Glick M "Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits. J Med Chem 2008, 51:2481-2491.
106. Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimisation. Curr Opin Chem Biol 2010, 14:467-474.
107. Zheng CJ, Han L, Yap CW, Xie B, Chen YZ. Progress and problems in the exploration of therapeutic targets. Drug Disc Today 2006, 11:412-420.
108. Dahmane T, Damian M, Mary S, Popot JL, Baneres JL. Amphipol-assisted in vitro folding of G protein-coupled receptors. Biochemistry 2009, 48:6516-6521.
109. Congreve M, Rich RL, Myszka DG, Figaroa F, Siegal G, Marshall FH. Fragment screening of stabilized G-protein coupled receptors using biophysical methods. Methods Enzymol 2011, 493:115-136.
110. 1 receptor. J Med Chem 2011, 54:7784-7796.
111. 2A receptor. J Med Chem 2011, 54:4312-4323.
112. Lawrence CK, ed. Fragment Based Drug Design: Tools, Practical Approaches and Examples, Methods in Enzymology. Vol. 493. Academic Press; 2011
113. Available at: http://practicalfragments.blogspot.com. (Accessed November 7, 2011).
114. Whittaker M, Law RJ, Ichihara O, Hesterkamp T, Hallett D. Fragments: past, present and future. Drug Disc Today: Technologies 2010, 7:e163-e171.
115. Bailey D, Boyd S, England P, de Esch I. Fragment-based drug design. Innovations Pharmaceutical Technol 2008, May: 18-22.
116. Leach AR, Hann MM, Burrows JN, Griffen EJ. Fragment screening: an introduction. Mol BioSystems 2006, 2:429-446.
117. Warr WA. Fragment-based drug discovery. J Comput Aid Mol Des 2009, 23:453-458.